• 1
    National Comprehensive Cancer Network. NCCN practice guidelines for breast cancer. Available at: http://www.nccn. org/professionals/physician_gls/PDF/breast.pdf Accessed August 1, 2008.
  • 2
    NIH Consensus Conference. Treatment of early-stage breast cancer. JAMA. 1991; 265: 391-395.
  • 3
    Veronesi U,Marubini E,Mariani L, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001; 12: 997-1003.
  • 4
    Fisher B,Anderson S,Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347: 1233-1241.
  • 5
    Morrow M,Bucci C,Rademaker A. Medical contraindications are not a major factor in the underutilization of breast conserving therapy. J Am Coll Surg. 1998; 186: 269-274.
  • 6
    Freedman G,Hanlon A,Fowble B,Anderson PR,Nicolaou N. Recursive partitioning identifies patients at high and low risk for ipsilateral tumor recurrence after breast conserving surgery and radiation. J Clin Oncol. 2002; 20: 4015-4021.
  • 7
    Perou CM,Sørlie T,Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000; 406: 747-752.
  • 8
    Sørlie T,Perou CM,Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001; 98: 10869-10874.
  • 9
    Garcia S,Dalès JP,Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 2007; 38: 830-841.
  • 10
    Rakha EA,Reis-Filho JS,Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol. 2008; 26: 2568-2581.
  • 11
    Nielsen TO,Hsu FD,Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004; 10: 5367-5374.
  • 12
    Haffty BG,Yang Q,Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006; 24: 5652-5657.
  • 13
    Nguyen PL,Taghian AG,Katz MS, et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. J Clin Oncol. 2008; 26: 2373-2378.
  • 14
    Kyndi M,Sørensen FB,Knudsen H, et al. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26: 1419-1426.
  • 15
    Greene FL,Page DL,Fleming ID, et al. eds. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. New York: Springer-Verlag; 2002.